Bariatrics Clinical Trial - Rhythm Pharmaceuticals RM 493-022

CONDITION(S): Obesity - TRIAL: Rhythm Pharmaceuticals RM 493-022 - The purpose of this protocol is to continue the assessment of setmelanotide treatment in patients who have successfully completed all critical study evaluations in a prior trial (index protocol) of setmelanotide for the treatment of obesity associated with genetic defects in the leptin-melanocortin pathway upstream of the MC4 receptor. The primary objectives of this extension trial are to explore the long-term safety and tolerability of setmelanotide for up to 5 years or until drug is otherwise available through authorized use. Patients can enter this protocol immediately upon completion of their index protocol such that dosing of setmelanotide continues without gaps in therapy.

Long Term Extension Trial of Setmelanotide

Drug

Setmelanotide

Trial Type

Interventional

Condition

Obesity

Keywords

Weight loss | Bariatrics